Patterns of kidney function decline associated with APOL1 genotypes: Results from AASK

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 8, 2016, Pages 1353-1359

  Tin, Adrienne ^a,b   Grams, Morgan E ^c   Estrella, Michelle ^c   Lipkowitz, Michael ^d   Greene, Tom H ^e   Kao, Wen Hong Linda ^a   Li, Liang ^f   Appel, Lawrence J ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AASK (African American Study of Kidney Disease and Hypertension); African Americans; Alleles; chronic kidney disease; Epidemiology and outcomes; Follow Up Studies; genetic renal disease; Genotype; glomerular filtration rate; Humans; hypertension; Kidney Diseases

Indexed keywords

AMLODIPINE; METOPROLOL; RAMIPRIL; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN L1; CREATININE;

ADULT; AGED; ALGORITHM; APOL1 GENE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; EVALUATION AND FOLLOW UP; FEMALE; GENE; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; GENOTYPING TECHNIQUE; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; MOLECULAR PATHOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROBABILITY; PROTEINURIA; RANDOMIZATION; SENSITIVITY ANALYSIS; AFRICAN AMERICAN; ALLELE; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; GENETICS; GENOTYPE; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; URINE;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; APOLIPOPROTEIN L1; CREATININE; DISEASE PROGRESSION; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85016932281     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12221115     Document Type: Article

References (22)

1. Zhong Y, Muñoz A, Schwartz GJ, Warady BA, Furth SL, Abraham AG:Nonlinear trajectory of GFR in children before RRT. J AmSoc Nephrol 25: 913-917, 2014
2. O’Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I, Todd-Stenberg J, Maynard C, Rodriguez RA, Murtagh FE, Larson EB, Williams DE: Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis 59: 513-522, 2012
3. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr., Greene TH: Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 59: 504-512, 2012
4. Grams ME, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, Appel LJ, Tin A, Coresh J: Race, APOL1 risk, and eGFR decline in the general population [published online ahead of print March 10, 2016]. J Am Soc Nephrol doi:ASN.2015070763
5. Rosansky SJ: Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. Am J Nephrol 36: 1-10, 2012
6. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr., Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. NEngl J Med 369: 2183-2196, 2013
7. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010
8. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345-350, 2010
9. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associatewith increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484-1491, 2013
10. O’Seaghdha CM, Parekh RS, Hwang SJ, Li M, Köttgen A, Coresh J, Yang Q, Fox CS, Kao WH: TheMYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 20: 2450-2456, 2011
11. Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, Hussain SK, Palella FJ Jr., Wolinsky SM, Martinson JJ, Parekh RS, Kao WH: The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis 60: 646-652, 2015
12. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, Fornage M, Parekh RS, Coresh J, Kao WH: Hemostatic factors, APOL1 risk variants, and the risk of end-stage renal disease in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol 10: 784-790, 2015
13. Freedman BI, Skorecki K: Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol 9: 2006-2013, 2014
14. Bodonyi-Kovacs G, Ma JZ, Lipkowitz MS, Kopp JB, Winkler CA, Le TH: Combined effects of GSTM1 null allele and APOL1 renal risk alleles in CKD progression in the African American Study of Kidney Disease and Hypertension Trial [published online ahead of print March 3, 2016]. J AmSoc Nephrol doi:ASN.2015050487
15. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JBCINKIJ; SK Investigators: Apolipoprotein L1 gene variants associate with hypertensionattributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114-120, 2013
16. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT: The rationale and design of the AASK cohort study. J Am Soc Nephrol 14[Suppl 2]: S166-S172, 2003
17. Gassman JJ, Greene T, Wright JT Jr., Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR: Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J AmSocNephrol 14 [Suppl 2]: S154-S165, 2003
18. Crainiceanu CM, Goldsmith AJ: Bayesian functional data analysis using WinBUGS. J Stat Softw 32: i11, 2010
19. Appel LJ, Wright JT., Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918-929, 2010
20. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484-1491, 2013
21. Chen TK, Choi MJ, Kao WH, Astor BC, Scialla JJ, Appel LJ, Li L, Lipkowitz MS, Wolf M, Parekh RS, Winkler CA, Estrella MM, Crews DC: Examination of potential modifiers of the association of APOL1 alleles with CKD progression. Clin J Am Soc Nephrol 10: 2128-2135, 2015
22. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR: Populationbased risk assessment of APOL1 on renal disease. J AmSocNephrol 22: 2098-2105, 2011